Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 12, 2026, 4:35 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 2,656 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Diabetes Treatment Clear all
Completed No phase listed Observational

Continuous Glucose Monitoring Self-Monitored Blood Glucose Type 2 Therapy Matrix Definition

NCT01390610
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Diabetic Blood Glucose Monitoring
Interventions
Not listed
Lead sponsor
HealthPartners Institute
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 25, 2015 · Synced Sep 12, 2026, 4:35 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Exenatide Once Weekly for Smoking Cessation

NCT02975297
View directory record Official record
Conditions
Smoking Cessation
Interventions
Exenatide, NRT, Counseling, Placebo
Drug · Behavioral
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 75 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 27, 2021 · Synced Sep 12, 2026, 4:35 AM EDT
Completed Phase 3 Interventional Results available

Insulin Lispro 6 Days Versus Insulin Aspart 6 Days in Pump Use

NCT01109316
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Insulin lispro 2 day reservoir in-use, Insulin lispro 6 day reservoir in-use, Insulin aspart 6 day reservoir in-use
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
13 Years and older
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
11
States / cities
Concord, California • Aurora, Colorado • Hollywood, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2019 · Synced Sep 12, 2026, 4:35 AM EDT
Terminated Phase 3 Interventional

Rimonabant In Prediabetic Subjects To Delay Onset Of Type 2 Diabetes

NCT00325650
View directory record Official record
Conditions
Prediabetic State
Interventions
Rimonabant, Placebo (for Rimonabant)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
35 Years to 75 Years
Enrollment
2,420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated May 17, 2016 · Synced Sep 12, 2026, 4:35 AM EDT
Completed Phase 2 Interventional

Peritransplant Deoxyspergualin in Islet Transplantation in Type 1 Diabetes

NCT00434850
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Allogeneic Pancreatic Islet Cells, Deoxyspergualin, Antithymocyte globulin, Daclizumab or basiliximab, Sirolimus, Tacrolimus, Etanercept
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
3
States / cities
San Francisco, California • Chicago, Illinois • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 15, 2016 · Synced Sep 12, 2026, 4:35 AM EDT
Suspended Not applicable Interventional

Evaluation of the Efficacy and Safety of DMR Using the Revita® in Subjects With Inadequately Controlled Type 2 Diabetes

NCT04419779
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Duodenal Mucosal Resurfacing (DMR), Duodenal Mucosal Resurfacing (Sham)
Device
Lead sponsor
Fractyl Health Inc.
Industry
Eligibility
21 Years to 70 Years
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
51
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Los Angeles, California + 39 more
Source: ClinicalTrials.gov public record
Updated Nov 12, 2025 · Synced Sep 12, 2026, 4:35 AM EDT
Not yet recruiting No phase listed Observational

Evaluation of the Clinical Spectrum of Diabetes and Obesity in Youth and Adults

NCT07388537
View directory record Official record
Conditions
Obesity, Diabetes, Metabolic Disorders
Interventions
Not listed
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
8 Years to 65 Years
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2055
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Sep 12, 2026, 4:35 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Allogeneic Mesenchymal Human Stem Cell Infusion Therapy for Endothelial DySfunctiOn in Diabetic Subjects With Symptomatic Ischemic Heart Disease. (ACESO-IHD)

NCT04776239
View directory record Official record
Conditions
Diabetes Mellitus, Ischemic Heart Disease
Interventions
100 million Allogeneic Mesenchymal Human Stem Cells, Placebo
Drug · Other
Lead sponsor
Joshua M Hare
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Sep 12, 2026, 4:35 AM EDT
Completed Not applicable Interventional

Promoting Physical Activity Among Bariatric Surgery Patients

NCT01722357
View directory record Official record
Conditions
Obesity
Interventions
Pedometer, Exercise Counseling
Behavioral
Lead sponsor
Ascension St. Vincent Carmel Hospital
Other
Eligibility
18 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2019
U.S. locations
1
States / cities
Carmel, Indiana
Source: ClinicalTrials.gov public record
Updated Jun 10, 2020 · Synced Sep 12, 2026, 4:35 AM EDT
Completed Not applicable Interventional Results available

Glycemic Control and Treatment Satisfaction Using Finesse Versus Pen for Initiating Bolus Insulin Dosing in Type 2 Diabetes Patients

NCT02542631
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Bolus Insulin Patch (Calibra Finesse), Insulin Pen (Novo-Nordisk FlexPen®)
Device
Lead sponsor
Calibra Medical, Inc.
Industry
Eligibility
22 Years to 75 Years
Enrollment
278 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
35
States / cities
Phoenix, Arizona • Escondido, California • Greenbrae, California + 28 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Sep 12, 2026, 4:35 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Glycemic Control, Safety and Tolerability of TC-6987 Monotherapy in Type 2 Diabetes Mellitus

NCT01293669
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
TC-6987, Placebo
Drug
Lead sponsor
Targacept Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
440 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
18
States / cities
Jonesboro, Arkansas • Mountain Home, Arkansas • Buena Park, California + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 12, 2013 · Synced Sep 12, 2026, 4:35 AM EDT
Terminated Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Effect of GLP-1 on Insulin Biosynthesis and Turnover Rates

NCT00609154
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
glucagon like peptide-1, glucose control
Drug · Dietary Supplement
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Feb 27, 2024 · Synced Sep 12, 2026, 4:35 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Euglycemia After Antenatal Late Preterm Steroids, the E-ALPS Study

NCT03076775
View directory record Official record
Conditions
Pregnancy Preterm, Neonatal Hypoglycemia, Hyperglycemia Drug Induced
Interventions
Maternal glycemic control
Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
86 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
2
States / cities
Birmingham, Alabama • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 25, 2022 · Synced Sep 12, 2026, 4:35 AM EDT
Active, not recruiting Phase 3 Interventional

A Study to Evaluate the Effect of Obicetrapib/Ezetimibe 10 mg Fixed-Dose Combination or Obicetrapib 10 mg Daily on Top of Guideline-Recommended Lipid-Lowering Therapy in Participants With Type 2 Diabetes and/or Metabolic Syndrome

NCT07219602
View directory record Official record
Conditions
Lipidemia, Type 2 Diabetes (T2DM), Metabolic Syndrome (MetS)
Interventions
obicetrapib 10 mg + ezetimibe 10 mg FDC daily, Obicetrapib 10 mg, Placebo
Drug · Other
Lead sponsor
NewAmsterdam Pharma
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
32
States / cities
Sun City West, Arizona • La Jolla, California • Pomona, California + 24 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Sep 12, 2026, 4:35 AM EDT
Terminated Phase 3 Interventional

Effect of Rimonabant and Metformin Combination on Glycemic Control in Patients With Type 2 Diabetes

NCT00690456
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Rimonabant, Placebo (for Rimonabant), Metformin
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
403 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated May 17, 2016 · Synced Sep 12, 2026, 4:35 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Subcutaneous Administration of Lisofylline to Healthy Normal Subjects and Subjects With Type 1 Diabetes

NCT00896077
View directory record Official record
Conditions
Healthy, Type 1 Diabetes
Interventions
Lisofylline
Drug
Lead sponsor
DiaKine Therapeutics, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 28, 2014 · Synced Sep 12, 2026, 4:35 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Healthy Living Partnerships to Prevent Diabetes in Veterans Pilot Study

NCT02835495
View directory record Official record
Conditions
Pre-diabetes, Obesity
Interventions
HELP Vets Intervention, Individual Education Program
Behavioral
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
21 Years and older
Enrollment
118 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
2
States / cities
Salisbury, North Carolina • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 23, 2020 · Synced Sep 12, 2026, 4:35 AM EDT
Completed Not applicable Interventional Results available

Feasibility of Outpatient Closed Loop Control With the iLet Bionic Pancreas in Cystic Fibrosis Related Diabetes

NCT03258853
View directory record Official record
Conditions
Cystic Fibrosis-related Diabetes
Interventions
Bionic Pancreas, Usual Care
Device · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
10 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 19, 2023 · Synced Sep 12, 2026, 4:35 AM EDT
Withdrawn Phase 2Phase 3 Interventional

Study Of Denagliptin In Subjects With Type 2 Diabetes Mellitus (T2DM)

NCT00387972
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
denagliptin (GW823093)
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
57
States / cities
Tallassee, Alabama • Phoenix, Arizona • Tucson, Arizona + 52 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2015 · Synced Sep 12, 2026, 4:35 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Treating Prediabetes in the First Trimester

NCT01926457
View directory record Official record
Conditions
Prediabetes, Gestational Diabetes
Interventions
Treatment of Prediabetes
Other
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older · Female only
Enrollment
202 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Oct 9, 2018 · Synced Sep 12, 2026, 4:35 AM EDT
Terminated Phase 4 Interventional Results available

Pilot Study of Bydureon to Treat Diabetes in HIV-infected Adults

NCT01791465
View directory record Official record
Conditions
Human Immunodeficiency Virus Infection, Diabetes Mellitus
Interventions
extended-release exenatide
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 99 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 9, 2017 · Synced Sep 12, 2026, 4:35 AM EDT
Recruiting Not applicable Interventional

Automated Insulin for Management of Intrapartum Glycemia

NCT06883344
View directory record Official record
Conditions
Type 1 Diabetes (T1D), Pregnancy, Pre-Gestational Diabetes
Interventions
Automated insulin delivery (AID) system, Intravenous (IV) insulin
Device · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 55 Years · Female only
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
3
States / cities
Los Angeles, California • San Diego, California • San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 12, 2026 · Synced Sep 12, 2026, 4:35 AM EDT
Active, not recruiting Not applicable Interventional

Expanding Delivery of an Evidence-based Weight-loss Intervention to Enhance Access and Reach Underserved Groups After TBI

NCT05699772
View directory record Official record
Conditions
Traumatic Brain Injury
Interventions
Telehealth-delivered Group Lifestyle Balance for people with TBI (tGLB-TBI), Brain Health Group (BHG)
Behavioral
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years to 80 Years
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 5, 2025 · Synced Sep 12, 2026, 4:35 AM EDT
Completed Phase 2 Interventional Results available

A Study to Assess the Safety and Efficacy of Oral Insulin in T2DM Patients With Nonalcoholic Steatohepatitis (NASH)

NCT04618744
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, NASH - Nonalcoholic Steatohepatitis
Interventions
ORMD-0801 (Insulin) capsule 8 mg BD, Placebo
Drug · Other
Lead sponsor
Oramed, Ltd.
Industry
Eligibility
18 Years to 70 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Tustin, California
Source: ClinicalTrials.gov public record
Updated Aug 6, 2024 · Synced Sep 12, 2026, 4:35 AM EDT